The mixture was vortex-mixed and centrifuged at 4000 rpm/5 min at 4 C

Baumert 1,9 , (1)University of Strasbourg, Inserm, Institut De Recherche Sur Les Maladies Virales Et Hpatiques Umr-S1110, 67000 Strasbourg, France, (2)Cnrs, Institut Pluridisciplinaire Hubert Curien Umr 7178, Strasbourg, France, (3)Institut Hospitalo-Universitaire, Ple Hpato-Digestif, Nouvel Hpital Civil, Strasbourg, France, (4)Department of Medicine, Division of Oncology, Massachusetts General Hospital, Boston, Harvard Medical School, Boston, USA, (5)Alentis Therapeutics, Basel, Switzerland, (6)Ihu-Strasbourg, Institute of Image-Guided Surgery, Strasbourg, France, (7)Division of Chronic Inflammation and Cancer, German Cancer Research Center, Heidelberg, Germany, (8)The M3 Research Institute, (9)Institut Hospitalo-Universitaire (IHU), Ple Hpato-Digestif, Hpitaux Universitaires De Strasbourg, 67000 Strasbourg, France Background: Cholangiocarcinoma (CCA) is a highly aggressive adenocarcinoma with unsatisfactory treatment options

The trial results at the 52nd week of a 54-month randomized, double-blind, placebo-controlled study (NCT03900429) involving Resmetirom were subsequently published [92]
Evidence and user reports indicate: Short term (24 weeks): improved hydration, smoother texture, and reduced redness due to better barrier repair and moisture balance